© Reuters. Senseonics vs. Tandem: Which Diabetes Stock is Better to Buy?
With the number of people with diabetes increasing, medical technology and devices that help diabetics live healthier lives are in great demand. Senseonics (SENS) and Tandem (TNDM) are two companies that focus on the treatment of diabetes. Which of these stocks is better to buy now? Healthcare is considered a recession-proof industry as people rarely postpone medical expenses. Most governments are also trying to prioritize health spending to make this sector even more relevant.
In addition, the demand for diabetes products continues to grow as cases increase worldwide. According to a report by the World Health Organization, around 422 million people worldwide have diabetes and the disease causes 1.6 million deaths each year.
With those factors in mind, today I’m going to analyze two diabetes stocks, Senseonics (SENS) and Tandem Diabetes Care (NASDAQ :), to see which stock is a better buy.
Read on on StockNews
Disclaimer: Fusion Media would like to remind you that the data contained on this website is not necessarily real time or accurate. All CFDs (stocks, indices, futures) and forex prices are not provided by exchanges, but by market makers. Therefore, prices may not be accurate and may differ from the actual market price, meaning that prices are indicative and not suitable for trading purposes. Therefore, Fusion Media is not responsible for any trading losses you may incur as a result of using this data.
Fusion Media or any other person involved in Fusion Media assumes no liability for any loss or damage that might arise from reliance on the information contained on this website, including data, prices, charts and buy / sell signals. Please inform yourself comprehensively about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment.
